ITP
Iron Triangle Partners Portfolio holdings
AUM
$632M
This Quarter Return
+24.2%
1 Year Return
+26.53%
3 Year Return
+134.07%
5 Year Return
+312.1%
10 Year Return
–
AUM
$713M
AUM Growth
+$713M
(+59%)
Cap. Flow
+$172M
Cap. Flow
% of AUM
24.12%
Top 10 Holdings %
Top 10 Hldgs %
60.98%
Holding
35
New
9
Increased
8
Reduced
4
Closed
9
Top Buys
| 1 |
Exact Sciences
EXAS
|
$66.2M |
| 2 |
UnitedHealth
UNH
|
$46.4M |
| 3 |
HCA Healthcare
HCA
|
$46M |
| 4 |
Haemonetics
HAE
|
$32.7M |
| 5 |
DexCom
DXCM
|
$27.7M |
Top Sells
| 1 |
Pacific Biosciences
PACB
|
$31.1M |
| 2 |
Hologic
HOLX
|
$23.8M |
| 3 |
Boston Scientific
BSX
|
$22.9M |
| 4 |
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
|
$17.2M |
| 5 |
Encompass Health
EHC
|
$16.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Exact Sciences
EXAS
$8.98B
| $66.2M | 8.59% | +500,000 | New | +$66.2M |
|
2
Zimmer Biomet
ZBH
$21B
| $57M | 7.39% | 370,000 +150,000 | +68% | +$23.1M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $47.5M | 6.16% | 650,000 +300,000 | +86% | +$21.9M |
|
|
4
UnitedHealth
UNH
$281B
| $46.4M | 6.02% | +132,442 | New | +$46.4M |
|
|
5
HCA Healthcare
HCA
$94.5B
| $46M | 5.97% | +280,000 | New | +$46M |
|
|
6
Encompass Health
EHC
$12.3B
| $41.3M | 5.36% | 500,000 -197,659 | -28% | -$16.3M |
|
7
Charles River Laboratories
CRL
$8.04B
| $35M | 4.53% | 140,000 +10,000 | +8% | +$2.5M |
|
|
8
Haemonetics
HAE
$2.63B
| $32.7M | 4.24% | +275,453 | New | +$32.7M |
|
9
Molina Healthcare
MOH
$9.8B
| $31.9M | 4.14% | 150,000 +50,000 | +50% | +$10.6M |
|
10
Envista
NVST
$3.52B
| $30.4M | 3.94% | 900,687 +600,687 | +200% | +$20.3M |
|
|
NVRO
11
DELISTED
NEVRO CORP.
NVRO
| $29.2M | 3.79% | 168,761 +8,761 | +5% | +$1.52M |
|
|
12
DexCom
DXCM
$29.5B
| $27.7M | 3.59% | +75,000 | New | +$27.7M |
|
13
Surgery Partners
SGRY
$2.91B
| $26.7M | 3.46% | 919,338 +169,338 | +23% | +$4.91M |
|
14
IQVIA
IQV
$32.4B
| $25.6M | 3.32% | 143,020 +3,020 | +2% | +$541K |
|
15
Guardant Health
GH
$8.41B
| $21.4M | 2.77% | 166,000 | – | – |
|
|
16
Pacific Biosciences
PACB
$393M
| $20.8M | 2.69% | 800,000 -1,200,000 | -60% | -$31.1M |
|
17
Heron Therapeutics
HRTX
$207M
| $18.3M | 2.37% | +865,072 | New | +$18.3M |
|
18
Vericel Corp
VCEL
$1.83B
| $17.9M | 2.32% | 580,000 | – | – |
|
|
CTLT
19
DELISTED
CATALENT, INC.
CTLT
| $16.7M | 2.16% | 160,000 -120,000 | -43% | -$12.5M |
|
20
CONMED
CNMD
$1.68B
| $16.6M | 2.15% | +148,317 | New | +$16.6M |
|
21
DaVita
DVA
$9.85B
| $16.4M | 2.13% | 140,000 -80,000 | -36% | -$9.39M |
|
22
Natera
NTRA
$23.1B
| $14.9M | 1.94% | +150,000 | New | +$14.9M |
|
23
Owens & Minor
OMI
$378M
| $12.3M | 1.59% | +454,419 | New | +$12.3M |
|
24
Outset Medical
OM
$247M
| $8.53M | 1.11% | 150,000 | – | – |
|
25
Royalty Pharma
RPRX
$15.6B
| $5.01M | 0.65% | 100,000 | – | – |
|